Pain burden in desmoid tumor patients: A survey of the French advocacy group SOS desmoid

Bulletin du Cancer

Volumn 102, Issue 3, 2015, Pages 213-216

  Rigaux, Philippe ^a   Lefebvre Kuntz, Danièle ^b   Penel, Nicolas ^a,b  

^a SOS Desmoïde   (France)

^b CENTRE OSCAR LAMBRET   (France)

Author keywords

Aggressive fibromatosis; Burden; Desmoid tumor; Pain

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; ANXIETY; ARTICLE; CANCER PAIN; CLINICAL TRIAL (TOPIC); DESMOID TUMOR; ECONOMIC ASPECT; FEMALE; FRANCE; HUMAN; IRRITABILITY; LEISURE; MAJOR CLINICAL STUDY; MALE; PAIN CLINIC; PAIN INTENSITY; PARTTIME EMPLOYMENT; SLEEP DISORDER; SOCIAL STATUS; STRUCTURED QUESTIONNAIRE; WORK CAPACITY; COMPLICATION; FIBROMATOSIS, AGGRESSIVE; HEALTH SURVEY; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SELF HELP; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; FIBROMATOSIS, AGGRESSIVE; FRANCE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SELF-HELP GROUPS; YOUNG ADULT;

EID: 84927757381     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2015.02.001     Document Type: Article

References (12)

1. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 2011;16:682-93.
2. Le Guellec, Soubeyran I, Rochaix P, Filleron T, Neuville A, Hostein I, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol 2012;25:1551-8.
3. Nieuwnhuis MH, Lefebvre JH, Bülow S, Järvinen H, Bertario L, Kernéis S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 2011;54:1229-34.
4. Carothers AM, Rizvi H, Hasson RM, Heit YI, Davids JS, Bertagnolli MM, et al. Mesenchymal stromal cell mutations and wound healing contribute to the aetiology of desmoids tumors. Cancer Res 2012;72:346-55.
5. Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchère-Vince D, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoids tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011;29:3553-8.
6. Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) Phase II Study. Pediatr Blood Cancer 2013;60:1108-12.
7. Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, et al. Imatinib for pre-agressive and recurrent aggressive fibromatosis (desmoids tumor): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011;22:452-7.
8. Garbay D, Le Cesne A, Penel N, Chevreau C, Marec-Berard P, Blay JY, et al. Chemotherapy in patients with desmoids tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012;23:182-6.
9. Mullen JT, Delaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012;19:4028-35.
10. Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E. Role of radiotherapy in the management of desmoids tumors. Int J Radiat Oncol Biol Phys 2011;80:787-92.
11. Cornelis F, Italiano A, Al-Ammari S, Kind M, Stoeckle E, Gangi A, et al. Successful iterative percutaneous cryoablation of multiple extra-abdominal desmoids tumors in a patient with Gardner syndrome. J Vasc Interv Radiol 2012;23:1101-3.
12. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Advanced aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol 2011;50:455-61.